Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
収録刊行物
-
- Leukemia
-
Leukemia 32 (4), 960-970, 2017-10-03
Springer Science and Business Media LLC